SPRB Stock Analysis: Buy, Sell, or Hold?

SPRB - Spruce Biosciences, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$53.60
-1.11 (-2.02%) ▼
5d: +7.39%
30d: +1.7%
90d: -8.9%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026

Get Alerted When SPRB Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: SPRB shows positive signals but monitor for confirmation. Market pricing in 19.1% decline. Moderate conviction.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$144.96
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$90.01
40.5% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.9x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: SPRB is currently trading at $53.59, which is considered extended relative to its 30-day fair value range of $48.63 to $52.60. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.1) compared to its historical average (20.9). Remarkably, the market is currently pricing in an annual earnings decline of 19.1% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, SPRB is in a strong downtrend. The price is approaching resistance at $54.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: SPRB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $149.71 (+173.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $48.63 - $52.60
Company Quality Score 51/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 61.9%

All Signals

  • BEARISH: Price extended above range
  • BULLISH: Strong technical setup (60/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 173.7% below Wall St target ($149.71)

Trading Range Analysis

30-Day Trading Range $48.63 - $52.60
Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $46.70
Resistance Level $54.32
Current Trend Strong Downtrend
Technical data as of Jun 9, 2026

Fundamental Context

Forward P/E (Next Year Est.) 11.05
Wall Street Target $149.71 (+173.7%)
Revenue Growth (YoY) -75.9%
Valuation Discount vs History -19.1% cheaper
PE vs Historical 11.1 vs 20.9 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -19.1% (market-implied from PE analysis)
1-Year Target $49.23 (-10%)
2-Year Target $44.31 (-19%)
3-Year Target $39.88 (-27%)
3-Yr Target (if PE normalizes) (PE: 11→21) $75.42 (+38%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.1 to 20.9
Stabilization Target: $103.46 (+89.1%)
PE Expansion Potential: +89.1%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: June 23, 2026 3:31 PM ET
Data refreshes hourly during market hours. Next update: 4:31 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for SPRB.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
REGN
Regeneron Pharmaceutical…
STRONG BUY
25 analysts
$833 67 BUY
IONS
Ionis Pharmaceuticals Inc
BUY
26 analysts
$105 64 BUY
DNLI
Denali Therapeutics Inc
STRONG BUY
19 analysts
$34 61 BUY
MLTX
MoonLake Immunotherapeut…
STRONG BUY
16 analysts
$28 65 BUY
BBIO
BridgeBio Pharma Inc
STRONG BUY
19 analysts
$102 65 BUY

More Analysis for SPRB

SPRB Technical Chart SPRB Price Prediction SPRB Earnings Date SPRB Investment Advisor SPRB Fair Price Analyzer SPRB Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals